Pharmacy

2:24
Accelerating clinical trials in transplantation
Charles Craddock
2:11
Regulatory approval of CPX-351 for secondary AML
Charles Craddock et al.
0:54
The switch to biosimilar rituximab at UCH: 12 months on
Simon Cheesman
2:14
CPX-351: liposomal daunorubicin and cytarabine for treating high-risk AML
Simon Cheesman
1:42
Patient education is important for drug tolerance and adherence
Jeanne McCarthy-Kaiser
1:52
The role of the pharmacist in transplant
Jeanne McCarthy-Kaiser
3:17
A pharmacoeconomic analysis of multiple myeloma treatment
Rafael Fonseca
4:56
Value and cost in MM treatment
Vincent Rajkumar
1:08
Subcutaneous daratumumab: combining efficacy, safety & convenience
Ajai Chari
1:09
Treating GvHD: current challenges and newly approved drugs
Katie Gatwood
1:43
The importance of pharmacist intervention in the treatment of GvHD with ruxolitinib and ibrutinib
Katie Gatwood
2:29
Ruxolitinib and ibrutinib: the future for GvHD treatment?
Katie Gatwood
1:29
The introduction of biosimilar rituximab: a case study from the pharmacist’s perspective
Simon Cheesman
4:02
Improving the Cancer Journey: update and the role of pharmacists
Trisha Hatt
1:54
Improving the NICE drug approval process
Man-Chie Chow
1:58
The importance of BOPA
Islam Elkonaissi
The content of VJHemOnc is intended for healthcare professionals